As AbbVie's Risankizumab Looms, Sun Pushes To 'Maximize Time' Of Ilumya

 
• By Anju Ghangurde

Sun says that it is "excited" with Ilumya’ s initial launch uptake in the crowded US psoriasis segment, but is pushing ahead with "speedy execution" of plans for the product before the potential arrival of new rivals such as AbbVie’s same-class therapy risankizumab.

Management
SUN IS KEEN TO PUSH AHEAD WITH PLANS FOR ILUMYA AS MORE COMPETITION LOOMS

More from Business

More from Scrip